Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SRRKBullishInsider Tradeinsider

High materiality8/10

SRRK director reports substantial share purchase

Oct 27, 2026, 8:32 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Repeated, sizable open-market purchases by a director are a notable bullish insider signal, though they do not guarantee future performance.

AI summary

What happened, with direct paths to the underlying reporting

Director AKKARAJU SRINIVAS reported a $2.04 million purchase of 48,988 SRRK shares at $41.59. A separate report in the provided records shows another purchase of about $1.94 million by the same director on October 23.

Reported purchase: 48,988 shares for about $2.04 million.
Same director also reported a separate purchase of about $1.94 million three days earlier.

Key facts

01
Insider: AKKARAJU SRINIVAS
02
Role: director
03
Transaction: P-Purchase
04
Shares: 48,988
05
Price: $41.59
06
Value: $2,037,411

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

SRRK director reports substantial share purchase

Key facts

FDA approves Scholar Rock therapy, creating near-term SRRK catalyst

Scholar Rock advances apitegromab path with alternate fill-finish and PMDA alignment

EU decision on SRRK SMA therapy delayed as FDA facility classification awaits

US FDA declines to approve Scholar Rock's muscle weakness drug